How should clinicians and patients choose antihyperglycemic agents? An evidence-based approach

Polskie Archiwum Medycyny Wewnetrznej

Volumn 121, Issue 6, 2011, Pages 208-212

  Montori, Victor M ^a   Deming, James ^b   Shah, Nilay D ^a  

^a MAYO CLINIC   (United States)

^b Mayo Clinic Health System   (United States)

Author keywords

Antihyperglycemic agents; Clinical decision making; Patient centered care; Type 2 diabetes

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; GLITAZONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; HEMOGLOBIN A1C; HYPERGLYCEMIC AGENT; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; MEGLITINIDE; METFORMIN; NATEGLINIDE; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA DERIVATIVE;

ARTICLE; BLOOD GLUCOSE MONITORING; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DIABETES MELLITUS; DRUG CHOICE; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; GASTROINTESTINAL SYMPTOM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT PREFERENCE; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 79959553833     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1059     Document Type: Article

References (21)

1. Montori VM, Fernández-Balsells M. Glycemic control in type 2 diabetes: time for an evidence-based about-face? Ann Intern Med. 2009; 150: 803-808.
2. Murad MH, Shah ND, Van Houten HK, et al. Individuals with diabetes preferred that future trials use patient-important outcomes and provide pragmatic inferences. J Clin Epidemiol. 2011; 64: 743-748.
3. Bennett WL, Maruthur NM, Singh S, et al. Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations. Ann Intern Med. 2011; 154: 602-613.
4. Selvin E, Bolen S, Yeh HC, et al. Cardiovascular outcomes in trials of oral diabetes medications: a systematic review. Arch Intern Med. 2008; 168: 2070-2080.
5. Dowling RJ, Goodwin PJ, Stambolic V. Understanding the benefit of metformin use in cancer treatment. BMC. Med. 2011; 9: 33.
6. Salpeter SR, Greyber E, Pasternak GA, Salpeter Posthumous EE. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2010: CD002 967.
7. Rao AD, Kuhadiya N, Reynolds K, Fonseca VA. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. Diabetes Care. 2008; 31: 1672-1678.
8. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet. 2007; 370: 1129-1136. (Pubitemid 47464583)
9. Loke YK, Singh S, Furberg CD. Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis. CMAJ. 2009; 180: 32-39.
10. Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. JAMA. 2007; 298: 1189-1195. (Pubitemid 47403105)
11. Lewis JD, Ferrara A, Peng T, et al. Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: interim report of a longitudinal cohort study. Diabetes Care. 2011; 34: 916-922.
12. Elashoff M, Matveyenko AV, Gier B, et al. Pancreatitis, Pancreatic and thyroid Cancer with Glucagon-Like Peptide-1-Based Therapies. Gastroenterology. 2011. [Epub ahead of print].
13. Gale EA. Insulin glargine and cancer: another side to the story? Lancet. 2009; 374: 521.
14. Eurich DT, Majumdar SR, McAlister FA, et al. Improved clinical outcomes associated with metformin in patients with diabetes and heart failure. Diabetes Care. 2005; 28: 2345-2351. (Pubitemid 41384275)
15. Breslin M, Mullan RJ, Montori VM. The design of a decision aid about diabetes medications for use during the consultation with patients with type 2 diabetes. Patient Educ Couns. 2008; 73: 465-472.
16. Mullan RJ, Montori VM, Shah ND, et al. The diabetes mellitus medication choice decision aid: a randomized trial. Arch Intern Med. 2009; 169: 1560-1568.
17. Shah ND, Mullan RJ, Breslin M, Yawn BP, Ting HH, Montori VM. Translating comparative effectiveness into practice: the case of diabetes medications. Med Care. 2010; 48 (6 Suppl): S153-S158.
18. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2009; 52: 17-30.
19. Wang AT, McCoy CP, Murad MH, Montori VM. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ. 2010; 340: c1344.
20. Aron D, Pogach L. Transparency standards for diabetes performance measures. JAMA. 2009; 301: 210-212.
21. Shah ND, Montori VM, Krumholz HM, et al. Responding to an FDA warning-geographic variation in the use of rosiglitazone. N Engl J Med. 2010; 363: 2081-2084.